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In recent years, the exploration of regulatory T cell (Treg)-based cellular therapy has 
become an attractive strategy to ameliorate inflammation and autoimmunity in various 
clinical settings. The main obstacle to the clinical application of Treg in human is their 
low number circulating in peripheral blood. Therefore, ex vivo expansion is inevitable. 
Moreover, isolation of Treg bears the risk of concurrent isolation of unwanted effector 
cells, which may trigger or deteriorate inflammation upon adoptive Treg transfer. Here, 
we present a protocol for the GMP-compliant production, lot-release and validation of 
ex vivo expanded Tregs for treatment of patients with autoimmune and inflammatory 
disorders. In the presented production protocol, large numbers of Treg, previously 
enriched from a leukapheresis product by using the CliniMACS® system, are ex vivo 
expanded in the presence of anti-CD3/anti-CD28 expander beads, exogenous IL-2 
and rapamycin during 21 days. The expanded Treg drug product passed predefined 
lot-release criteria. These criteria include (i) sterility testing, (ii) assessment of Treg phe-
notype, (iii) assessment of non-Treg cellular impurities, (iv) confirmation of successful 
anti-CD3/anti-CD28 expander bead removal after expansion, and (v) confirmation of 
the biological function of the Treg product. Furthermore, the Treg drug product was 
shown to retain its stability and suppressive function for at least 1 year after freezing 
and thawing. Also, dilution of the Treg drug product in 0.9% physiological saline did not 
affect Treg phenotype and Treg function for up to 90 min. These data indicate that these 
cells are ready to use in a clinical setting in which a cell infusion time of up to 90 min 
can be expected. The presented production process has recently undergone on site 
GMP-conform evaluation and received GMP certification from the Bavarian authorities 
in Germany. This protocol can now be used for Treg-based therapy of various inflam-
matory and autoimmune disorders.
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INtroDUctIoN
Regulatory T cells (Treg) play a critical role in maintaining immune 
homeostasis and limiting autoimmune responses by modulation 
of both innate and adaptive immunity (1). Classically defined 
Treg are characterized by their constitutive expression of CD4, 
CD25, and FoxP3 (2) and nearly absent expression of CD127 
(3, 4). They can be divided in (i) natural Treg originating from the 
thymus and peripherally induced Treg, which differentiate from 
naïve T cells when self or non-self antigen is encountered under 
tolerogenic conditions (5, 6). Their existence in humans has first 
been described in 2001, when several groups were able to isolate 
(7–9) and expand (10) suppressive CD4+CD25+ T  cells from 
human peripheral blood. Animal studies have shown that Treg 
successfully prevent type I diabetes, experimental autoimmune 
encephalitis, rheumatoid arthritis, inflammatory bowel disease, 
systemic lupus erythematosus, scurfy disease, graft-versus-host 
disease, and transplant rejection (11). As a result, the exploration 
of Treg-based cellular therapy has become an attractive strategy 
to induce tolerance in various clinical settings in patients (12). 
However, the main obstacle to clinical application of Treg in 
humans is their low number circulating in peripheral blood. 
Therefore, initial Treg enrichment and subsequent expan-
sion protocols are necessary to generate clinical relevant Treg 
numbers. Treg enrichment from a peripheral blood product is 
challenging, since activated conventional human T cells may also 
express CD25 (13). As a result, isolation of Treg bears the risk of 
concurrent isolation of unwanted effector cells.
Currently, three main strategies to isolate and expand highly 
enriched Treg populations from a human blood product are 
exploited by several research groups. First, Treg can be isolated 
and expanded from a donor-derived umbilical cord blood prod-
uct (14–17), yet this approach is not feasible in other settings 
than stem cell transplantation, since it cannot be excluded that 
allogeneic donor-derived Treg itself induce graft-versus-host 
like reactions in non-transplant patients. Alternatively, highly 
enriched Treg populations can be isolated using good manufac-
turing practice (GMP)-approved flow cytometry-based (FACS) 
cell sorters (18–20) or the mTOR inhibitor rapamycin can be 
added to the cell culture process to inhibit the proliferation of 
contaminating effector T cells (21–23) The latter is a calcineurin 
inhibitor that is widely used to prevent allograft rejection after 
transplantation (24). Previous animal studies showed that 
rapamycin decreases the number of CD4+ cell subsets in mice, 
but increases the number of functional Treg (25). Based on 
these findings, Ogino et  al. provided the proof-of-concept that 
mouse CD4+ T cells can be expanded ex vivo in the presence of 
rapamycin (26). The addition of rapamycin to the cell cultures 
affected overall expansion efficiency but effectively inhibited the 
outgrowth of non-suppressive effector T  cells. In addition, the 
rapamycin-expanded Treg ameliorated colitis in an SCID mouse 
model.
Safinia et al. (27) were the first to establish a GMP-compliant 
production protocol to expand CD25+-enriched cells from 
peripheral blood in the presence of rapamycin with the intention 
to prevent rejection after liver transplantation. In their 36-day 
expansion protocol, multiple rounds of in vitro Treg stimulation 
are necessary to reach clinically relevant Treg numbers. This may 
result in loss of FoxP3 expression and epigenetic stability, thus 
increasing the risk of in  vivo Treg conversion into unwanted 
inflammatory effector cells.
Here, we provide the CD25+ enrichment protocol, ex vivo 
expansion protocol as well as the validated lot-release protocols 
that have been approved by the German regulatory authorities 
for a Treg drug product intended for clinical use in patients with 
autoimmune and inflammatory disorders. Treg produced by this 
21-day protocol are epigenetically stable, suppressive and contain 
less than 0.1% of contaminating CD8+ effector cells. Moreover, 
we demonstrate the stability of the Treg drug product both after 
storage for up to 12 months and after subsequent dilution in a 
0.9% physiological saline infusion solution. Also, we show that 
the Treg drug product remains polyclonal after 21 days of expan-
sion and expresses various receptors associated with lymphocyte 
trafficking to secondary lymphoid organs and sites of inflam-
mation. The protocol is scheduled to produce Treg for a phase I 
dose-escalation in patients and serves as an add-on platform for 
the adoptive transfer of Treg in a broad range of autoimmune and 
inflammatory disorders.
MAtErIAl AND MEtHoDs
Ethical considerations
This study was approved by the local Institutional Review Board 
(IRB) of the Friedrich-Alexander-Universität Erlangen-Nürnberg 
under IRB number 151_12 B. In agreement with IRB approval 
and in accordance with the Declaration of Helsinki, oral and writ-
ten consent was obtained from all healthy donors who donated 
blood for this study.
Materials and Equipment
The following materials are used during the Treg production 
process:
Autologous leucapherisate
Autologous plasma
MACS® GMP ExpAct Treg Kit Miltenyi Biotec (# 170-076-119)
Human serum albumin Baxter (# PL 00116/0620)
MACS® GMP Rapamycin Miltenyi Biotec (# 170-076-308)
CliniMACS® CD8 Reagent Miltenyi Biotec (# 275-01)
CliniMACS® CD19 Reagent Miltenyi Biotec (# 179-01)
CliniMACS® CD25 Reagent Miltenyi Biotec (# 274-01)
l-Glutamine Lonza (# BE 17-605 E)
CliniMACS® PBS/EDTA Miltenyi Biotec (# 700-25)
IL-2 (Proleukin®) Novartis Pharma (# PZN 02238131)
X-VIVO15 Lonza (# BE 04-744)
Dimethyl sulfoxide (DMSO) Sigma-Aldrich (# D2438)
Glucose solution 40% (Glucosteril 40%) Frescenius Kabi Deutschland GmbH
treg Manufacture
A detailed overview of the manufacturing process is provided 
in Figure 1. The complete manufacturing process is performed 
in the GMP facility of the department of dermatology at 
the Friedrich-Alexander Universität Erlangen-Nürnberg. The 
manufacturing process is approved by the Bavarian Authorities 
under number DE_BY_05_MIA_2017_0012/55.2-2678.3-41-4-16. 
FIGUrE 1 | Flowchart of the production of the regulatory T cell (Treg) drug substance and Treg drug product.
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All cell purification steps are performed by using a CliniMACS® 
system (Miltenyi Biotec, Bergisch Gladbach, Germany) in con-
junction with ISO certified CliniMACS® CD8 (Miltenyi Biotec, 
275-01), CD19 (Miltenyi Biotec, 179-01), and CD25 (Miltenyi 
Biotec, 274-01) bead reagents. All purification steps are performed 
with GMP-grade CliniMACS® PBS/EDTA buffer (Miltenyi 
Biotec, 700-25) supplemented with clinical grade human serum 
albumin (Baxter, PL 00116/0620, PEI.H.03272.01-1). This buffer 
is hereafter called PBS–HSA–EDTA. All cell culture steps were 
performed in the presence of X-VIVO 15 medium without 
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gentamicin and phenol red (Lonza, BE 04-744) supplemented 
with heat inactivated autologous plasma, clinical grade IL-2 
(1,000 IU/ml, Proleukin® S, Aldesleukin, Novartis Pharma, PZN 
02238131), MACS® GMP rapamycin (100 ng/ml, Miltenyi Biotec, 
170-076-308), and l-glutamine (200 mM, Lonza, BE 17-605 E). 
This medium is hereafter called complete autologous culture 
medium.
A leukapheresis product (department of Transfusion Medi-
cine, Friedrich-Alexander Universität Erlangen-Nürnberg, 
Erlangen, Germany) is used as cell source for initial CD25+ cell 
enrichment.
CD25+ Cell Isolation
The operating procedures to enrich or deplete select cell subsets 
from a leukapheresis product are standardized and provided by 
the manufacturer of the CliniMACS® device (Miltenyi Biotec). 
Upon arrival in the GMP facility, the leucapherisate is diluted 
1 + 3 with PBS–HSA–EDTA buffer and subsequently centrifuged 
at 200 g for 15 min at 22°C. After centrifugation, the supernatant 
is removed, the leucapherisate is resuspended in PBS–HSA–
EDTA and centrifuged at 300 g for 15 min at 4°C. After this cen-
trifugation step and subsequent removal of the supernatant, the 
leucapherisate is resuspended in 380 ml of cold PBS–HSA–EDTA 
and labeled with CliniMACS® CD25 reagent. The CliniMACS® 
CD25 bead reagent specifically labels up to 600 × 106 CD25+ cells 
within a total population consisting of maximal 40 × 109 white 
blood cells. These CliniMACS® acceptance criteria are provided 
by Miltenyi Biotec. If one of these acceptance criteria is not met, a 
maximum of two portions, instead of one portion, of CliniMACS 
CD25 bead reagent are used to specifically label the leucapheri-
sate. CD25-labeling is performed during 15 ± 2 min at 2–8°C at 
a cell shaker programmed at 25 rpm. After labeling is completed, 
the cell suspension is washed with PBS–HAS–EDTA, diluted in 
100  ml PBS–HSA–EDTA and transferred into a cell collection 
bag. CD25+ enrichment is performed by using the automatic 
CliniMACS® ENRICHMENT 3.2 program of the CliniMACS® 
device according to the manufacturer’s instructions. The CD25+ 
enriched cell fraction is used for further manufacturing.
start of cD25+ cell Expansion on Day 0
Cell count and viability of the CD25+ cells was determined on two 
samples of 40 µl by trypan blue staining according to European 
Pharmacopeia (Ph. Eur.) 2.7.29. Depending on cell number, 
CD25+ cells were seeded at a density of 0.5 × 105 cells/ml in a 
24-well or 6-well culture plate in complete autologous culture 
medium. To facilitate in  vitro CD25+ cell expansion, clinical 
grade IL-2 (1,000 IU/ml), rapamycin (100 ng/ml), and anti-CD3/
anti-CD28 expander beads (MACS® GMP ExpAct Treg Kit, 
Miltenyi Biotec) were added at a bead-to-cell ratio of 4:1 to the 
cell cultures. Cell cultures were gently mixed and incubated at 
37 ± 1°C, 5 ± 1% CO2, >70% r.h. for 4 days.
Addition of Supplements at Day 4
At day 4, fresh IL-2 (1,000 IU/ml) and rapamycin (100 ng/ml) 
were added to the cell cultures to substitute for cellular consump-
tion. Cell cultures were gently mixed and incubated at 37 ± 1°C, 
5 ± 1% CO2, >70% r.h. for 3 days.
Addition of Supplements and Medium on Day 7
At day 7, cell culture plates were collected from the incubator, 
and the total cell culture volume transferred into a T75 flask. Cell 
count and viability of the CD25+ cells was determined on two 
samples of 40  µl by trypan blue staining according to Ph. Eur. 
2.7.29. Depending on cell number, the cell density was adjusted 
to 0.5 × 106 cells/ml by adding fresh complete autologous culture 
medium, and the cell suspension was seeded in new culture plates. 
To substitute for cellular consumption, fresh IL-2 (1,000 IU/ml) 
and rapamycin (100 ng/ml) were added. Cell cultures were gently 
mixed and incubated at 37 ± 1°C, 5 ± 1% CO2, >70% r.h. for 4 days.
Addition of Supplements and Medium on Day 11
Analogous to day 7, cell culture plates were collected from the 
incubator, and the cell suspension, depending on the volume, 
transferred into a T75 or 1 l cell culture flask. Cell count and viabil-
ity of the CD25+ cells was determined on two samples of 40 µl by 
trypan blue staining according to Ph. Eur. 2.7.29. Depending on 
cell number, the cell density was adjusted to 0.5 × 106 cells/ml by 
adding fresh complete autologous culture medium. Depending 
on total volume, the cell suspension was seeded in T75 or T175 
cell culture flasks. To substitute for cellular consumption, fresh 
IL-2 (1,000 IU/ml) and rapamycin (100 ng/ml) were added. Cell 
cultures were gently mixed and incubated at 37 ± 1°C, 5 ± 1% 
CO2, >70% r.h. for 3 days.
Depletion of CD8+ and CD19+ Cells on Day 14
At day 14, cell culture flasks were collected from the incubator, 
and the cell suspension, depending on the volume, transferred 
into a T75 or 1 l cell culture flasks. Cell count and viability of the 
CD25+ cells was determined on two samples of 40 µl by trypan 
blue staining according to Ph. Eur. 2.7.29. To deplete potentially 
contaminating CD8+ and CD19+ cells, the CD25+ cell product was 
magnetically labeled with CliniMACS® CD8 and CliniMACS® 
CD19 bead reagent according to the manufactures’ instructions. 
Specifically, up to 4 × 109 CD8+ cells and up to 5 × 109 CD19+ 
cells within a total population consisting of maximal 40 × 109 cells 
may specifically be labeled by 7.5  ml of the CliniMACS® CD8 
bead reagent and CliniMACS® CD19 bead reagent, respectively. 
These CliniMACS® acceptance criteria were provided by Miltenyi 
Biotec. In general, CD25+ cell expansion on day 14 does not result 
in total cell numbers above 1 × 109 total cells, and the relative con-
tamination with CD8+ and/or CD19+ cells is assumed to be below 
25%. Therefore, a predefined aliquot of 1.875 ml of CliniMACS® 
CD8 bead reagent and CliniMACS® CD19 bead reagent is used 
to label up to 1.0 × 109 CD8+ cells and up to 1.25 × 109 CD19+ 
cells within a total population consisting of maximal 10 ×  109 
cells. For depletion of CD8+ and CD19+ cells, sterile CliniMACS® 
PBS/EDTA buffer supplemented with human serum albumin 
is used. Depletion of CD8+ and CD19+ cells is performed by 
using the automatic CliniMACS® DEPLETION 2.1 program 
of the CliniMACS® device. This program facilitates automated 
magnetic depletion of CD8+ and CD19+ cells in a closed, sterile 
system. Two cell fractions are collected into bags according to 
the instrumental settings of the CliniMACS® DEPLETION 2.1 
program. The CD8+- and CD19+-depleted cell fraction 2 is used 
for further processing.
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Cell number in fraction 2 is determined on two samples of 
40 µl by trypan blue staining according to Ph. Eur. 2.7.29. CD25+/
CD8−/CD19− cells of fraction 2 obtained from the CliniMACS® 
device are continued to be cultivated in vitro. Depending on cell 
number, the cell density was adjusted to 0.5 ×  106  cells/ml by 
adding fresh complete autologous culture medium. Depending 
on total volume, the cell suspension was seeded in T75 or T175 
cell culture flasks. To compensate for any anti-CD3/anti-CD28 
bead removal during the CD8+ and CD19+ cell depletion process, 
anti-CD3/anti-CD28 beads (analogously to the amount of beads 
used at day 0) are added to the cell cultures. Finally, fresh IL-2 
(1,000  IU/ml) and rapamycin (100  ng/ml) were added. Cell 
cultures were gently mixed and incubated at 37 ± 1°C, 5 ± 1% 
CO2, >70% r.h. for 4 days.
Addition of Supplements and Medium on Day 18
Analog to days 7 and 11, cell culture plates or flasks were col-
lected from the incubator, and the cell suspension, depending on 
the volume, transferred into a T75 or 1 l cell culture flasks. Cell 
count and viability of the CD25+ cells was determined on two 
samples of 40  µl by trypan blue staining according to Ph. Eur. 
2.7.29. Depending on cell number, the cell density was adjusted 
to 0.5 × 106 cells/ml by adding fresh complete autologous culture 
medium. Depending on total volume, the cells are subsequently 
seeded in T75 or T175 cell culture flasks. To substitute for cellular 
consumption, fresh IL-2 (1,000 IU/ml) and rapamycin (100 ng/ml) 
are added. Cell cultures are gently mixed and incubated 
(37 ± 1°C, 5 ± 1% CO2, >70% r.h.) for an additional 3 days.
Harvesting of CD25+ Cells at Day 21
At day 21, cell culture plates or flasks are collected from the 
incubator, and the total cell culture volume is transferred into a 
set of 50 ml centrifuge tubes. Culture flasks are washed once with 
approximately 10–20 ml of PBS/EDTA buffer supplemented with 
human serum albumin. Used washing buffer is also transferred 
into the 50 ml centrifuge tubes. Tubes are centrifuged, superna-
tants are discarded, and pellets are collected into a set of 50 ml 
centrifuge tubes by resuspending pellets with approximately 
5  ml of PBS/EDTA buffer supplemented with human serum 
albumin. Cell count and cell viability of CD25+/CD8−CD19− cells 
are determined on two samples of 40 µl by trypan blue staining 
according to Ph. Eur. 2.7.29.
Anti-CD3/Anti-CD28 Expander Bead and CD25-, 
CD8-, and CD19-Labeling Bead Removal on Day 21
A maximum of 2.04  ×  1010 beads can be depleted from a 
maximum of 4 ×  1010 CD25+ cells in a final concentration of 
20 × 106–400 × 106/ml during the bead removal process. These 
CliniMACS® acceptance criteria are provided by Miltenyi Biotec. 
In general, CD25+ cell expansion on day 21 does not result in total 
cell numbers above 4 × 1010 total cells. Therefore, the assumed 
maximum amount of added beads is 0.48 × 1010 [four times the 
maximum amount of isolated CD25+ cells at day 0 (1,200 × 106)]. 
For bead removal, sterile CliniMACS PBS/EDTA buffer sup-
plemented with human serum albumin is used. Bead removal 
is performed by using the automatic CliniMACS® DEPLETION 
2.1 program of the CliniMACS® device. The CliniMACS® device 
facilitates automated magnetic depletion of anti-CD3/anti-CD28 
expander beads and CD25-, CD8-, and CD19-labeling beads 
in a closed, sterile system. Two cell fractions are collected into 
bags according to the instrumental settings of the CliniMACS® 
DEPLETION 2.1 program. The bead-depleted cell fraction 2 is 
used for filling and storage.
Filling and Storage of the CD25+ Cells at Day 21
The bead-depleted cells are transferred into a set of 50 ml cen-
trifuge tubes. Tubes are centrifuged, supernatants are discarded, 
and pellets are collected into 100 ml of PBS/EDTA buffer sup-
plemented with human serum albumin. The final cell number in 
cell fraction 2 after bead removal is determined on two samples of 
40 µl by trypan blue staining according to Ph. Eur. 2.7.29. Before 
filling and storage, a freezing medium is freshly prepared in a ster-
ile bottle. The total volume is calculated based on the cell counting 
results obtained after the first centrifugation step after the anti-
CD3/anti-CD28 bead removal step. The freezing medium con-
sists of human serum albumin, DMSO, and 40% glucose solution 
(hereafter called freezing medium). After definition of the final 
CD25+ cell number, cells are centrifuged and depending on cell 
number resuspended in an appropriate volume of human serum 
albumin at a final concentration of 20 × 106 viable cells/ml. Five 
hundred microliters of cell suspension are filled into each cryovial 
(1.0 ml total volume). After addition of 500 µl freezing medium 
(55.5 Vol.-% human serum albumin, 25.0 Vol.-% DMSO, and 20.0 
Vol.-% glucose) to every vial, the closed vials are mixed gently and 
transferred immediately into a freezing container. The container 
is than stored immediately at −75 ± 10°C for 4–18 h. The vials 
are transferred to the gas phase of liquid nitrogen (≤−150°C) for 
up to 2 years.
treg lot-release
Assessment of Treg Drug Product Identity  
and Cellular Composition
Throughout the manuscript, Treg are defined as 
CD4+CD25+CD127− cells (=Treg drug product identity) based on 
previously published data (3, 4). Treg drug product identity was 
determined before and after 21 days of expansion by staining with 
directly conjugated mouse antihuman antibodies (mAbs) against 
CD4 (FITC, clone RPA-T4), CD25 (FITC, clone M-A251), and 
CD127 (PE, clone RDR5). Treg drug product cellular composi-
tion was determined before and after 21  days of expansion by 
staining with directly conjugated mouse antihuman mAbs against 
CD8 (FITC, clone SK1), CD19 (FITC, clone SJ25C1), CD16 (PE, 
clone 3G8), and CD56 (PE, clone B159). Corresponding IgG1,κ 
mouse isotype controls (FITC, clone MOPC-21 and PE, clone 
MOPC-21) were included to assess unspecific binding. Potential 
dead cells were excluded by labeling with propidium iodide (PI) 
(BD Biosciences) according to the manufacturer’s instructions. 
Cells were acquired using a FACS Calibur (BD Biosciences), and 
data were analyzed using CellQuest™ Pro (BD Biosciences) soft-
ware. For information-only purposes, cells were intracellularly 
stained with FoxP3 (clone PCH101) using a FoxP3/Transcription 
Staining Buffer Set (eBioscience, San Diego, CA, USA) according 
to the manufacturer’s instructions.
tABlE 1 | Validation results of analysis by flow cytometry.
Validation part Parameter Acceptance result Passed
Reproducibility Coefficient of variation ≤5% 0.3 2.0% X yes □ no
0.5 2.5%
0.7 0.8%
Intermediate precision Deviation of mean ≤10% 0.3 8.7% X yes □ no
0.5 4.9%
0.7 7.1%
Coefficient of variation ≤8% 0.3 5.6% X yes □ no
0.5 3.8%
0.7 4.0%
Linearity Correlation ≥0.9 1,000 X yes □ no
Linear regression n.a. y = 0.973x + 0.002 X yes □ no
Range Cell fraction 0.04–1 0.04–1 X yes □ no
Accuracy Deviation from actual value 0.3 ± 0.03 0.3 0.022 X yes □ no
0.5 ± 0.05 0.5 0.019
0.7 ± 0.07 0.7 0.014
Recovery 100 ± 10% 0.3 92.8% X yes □ no
0.5 96.1%
0.7 98.1%
Limit of detection Quantification limit (QL) (10,000 cells) ≤0.04 0.016 X yes □ no
Limit of detection CD8 QL (300,000 cells) ≤0.001 0.001 X yes □ no
Specificity Fluorescence in channel 1 or 2 Meets specificity Meets specificity for all antibodies tested X yes □ no
Efficiency of antibodies Fraction of positive cells Within range of development All antibodies within range X yes □ no
Positive cells and negative cells were mixed at the indicated fractions 0.3, 0.5, and 0.7 to represent 30, 50, and 70% of the final cell mixture. For reproducibility, triplicate analysis 
of three different fractions of positive cells was statistically analyzed by coefficient of variation. The analysis of a different person on a different day was used to determine the 
intermediate precision. To determine linearity, 10 different fractions of positive cells were analyzed by correlation factor and linear regression. These results were compared with  
the theoretical real fraction contents to determine accuracy. The limits of detection were determined by analyzing six negative cell fractions and calculated with the formula:  
10s/a (s indicating SD and a indicating slope of regression). Antibody specificity and efficiency were determined by using positive and negative cell fractions, respectively.
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In general, flow cytometry is performed as described in 
Ph. Eur. 2.7.24. The specific method for flow cytometry was 
validated, since it is not in detail described in the Ph. Eur. In 
brief, thawed dendritic cells were used to validate the method 
for flow cytometry. Thawed dendritic cells, thawed lymphocytes, 
thawed Treg, and thawed CD25− cells were used to determine 
specificity. Lymphocytes were single stained with CD4, CD127, or 
CD8 antibody, respectively, fixed with 1% formaldehyde, washed 
twice and subsequently mixed with unstained lymphocytes 
of the same preparation. To determine specificity of the CD25 
antibody, Treg were single stained with the CD25 antibody, fixed 
with 1% formaldehyde, washed twice and subsequently mixed 
with unstained Treg of the same preparation The FACS result for 
stained lymphocytes or Treg was set to 1 (=100% positive). For 
specificity purposes, optimal positive and negative cells for each 
antibody characterizing the Treg drug product were measured. 
Nominal negative cells shall show less than 0.04 (=4%) posi-
tive cells, and nominal positive cells shall show more than 0.04 
(=4%) positive ones. Summarized results are shown in Table 1. 
In addition, the stringent cutoff of less than 0.1% contaminating 
CD8+ cells in the final Treg product was validated separately. To 
avoid false negative CD8+ values in the final Treg product, the 
number of to acquire cells was increased to 300,000. A total of 
six acquisitions were performed with mature monocyte-derived 
dendritic cells, which represented the CD8− cell subset. The SD 
(s) was calculated from all acquired “CD8+” cells within the 
CD8− mature dendritic cell subset, and the quantification limit 
(QL) was calculated based on the following formula: QL = 10s/a 
with a set to 0.973 (=linear regression value derived from the flow 
cytometry validation report) (data not shown).
Assessment of Treg Drug Product Purity
Regulatory T cell drug product purity was determined after anti-
CD3/anti-CD28 expander bead removal by staining with directly 
conjugated mouse antihuman IgG3,κ Labeling Check PE (clone 
AC146, Miltenyi Biotec) and APC (clone AC146, Miltenyi Biotec). 
Samples were acquired using a FACS Calibur (BD Biosciences), 
and data were analyzed using CellQuest™ Pro (BD Biosciences) 
software.
The method to measure anti-CD3/anti-CD28 expander bead 
and CD25-, CD8- and CD19-labeling bead contamination was 
validated since it is not described in a Ph. Eur. Specifically, thawed 
lymphocytes were mixed with predefined amounts of anti-CD3/
anti-CD28 expander beads and incubated for 1 h at 37°C at 5% 
CO2. After 1 h of incubation, cells were lysed using saponin 0.2% 
(Sigma-Aldrich, St. Louis, MI, USA) to also capture potential 
intracellular beads. Subsequently, beads were stained by flow 
cytometry with Labeling Check Reagent PE and Labeling Check 
Reagent APC as described above. To determine bead contamina-
tion, all samples were acquired with the use of Trucount® tubes 
tABlE 2 | Validation results of analysis of anti-CD3/anti-CD28 bead 
contamination.
Validation part Parameter Acceptance result Passed
Reproducibility Coefficient of 
variation
≤25 750
1,000
3,000
7.1
8.7
22.7
X yes □ no
Intermediate 
precision
F-value <9.28 750
1,000
3,000
1.54
5.50
2.49
X yes □ no
Deviation from 
mean
≤15% 750
1,000
3,000
6.5
14.1
7.3
X yes □ no
Coefficient of 
variation
≤25 750
1,000
3,000
14.0
13.3
17.6
X yes □ no
Linearity Coefficient of 
correlation
≤0.98 0.996 X yes □ no
Range Detection range 300–6,000 300–6,000 X yes □ no
Accuracy Mean 637–863
850–1,150
2,400–3,600
750
1,000
3,000
689
1,105
3,420
X yes □ no
Retrieval rate ±15%
±15%
±20%
750
1,000
3,000
8.1%
10.5%
14.0%
X yes □ no
Limit of 
detection
QL <400 390 X yes □ no
Specificity Positive particle >400 1,105 X yes □ no
Negative particle <400 38 X yes □ no
A total of 750, 1,000, and 3,000 anti-CD3/anti-CD28 expander beads were mixed 
with 100 × 106 peripheral blood mononuclear cells. For reproducibility, triplicate 
analysis of indicated cell-bead mixtures was statistically analyzed by coefficient of 
variation. The analysis of a different person on a different day was used to determine 
the intermediate precision. To determine linearity, 10 different cell-bead mixtures were 
analyzed by correlation factor and linear regression. These results were compared with 
the theoretical real fraction contents to determine accuracy. The limits of detection 
were determined by analyzing six bead-negative cell mixtures and calculated with the 
formula: 10s/a (s indicating SD and a indicating slope of regression). Specificity was 
determined by using bead-positive and bead-negative cell mixtures, respectively.
QL, quantification limit.
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(BD Biosciences) to assure standardized acquisition. Nominal 
samples negative for beads should show less than 400 beads, 
nominal samples positive for beads should show more than 
400 beads. At least 100 × 106 Treg drug product cells should be 
lysed, labeled with Labeling Check Reagent PE and Labeling 
Check Reagent APC and subsequently measured to define bead 
contamination in the final Treg drug product. The results of the 
validation are summarized in Table 2.
Assessment of Treg Drug Product Function
The method to assess Treg drug product function was validated, 
since it is not described in the Ph. Eur. Specifically, cryopreserved 
autologous CD25− cells were thawed, washed, and labeled 
with 5  µM carboxyfluorescein succinimidyl ester (CFSE) 
(ThermoFisher Scientific, Carlsbad, CA, USA). Next, CFSE-
labeled CD25− cells (containing CD4+ and CD8+ cells; hereafter 
called responder cells) were cocultured with thawed day 21 Treg 
drug product cells (hereafter called Treg) at a Treg to responder 
cell ratio of 1 + 1, 1 + 5, and 1 + 10. Cocultures were stimulated 
with anti-CD3 and anti-CD28 coated beads (MACS GMP ExpAct 
Treg Kit, Miltenyi Biotec) at a bead-to-cell ratio of 1 + 1. Negative 
controls included responder cells alone and Treg +  responders 
cells at a ratio of 1 +  1 without the addition of anti-CD3 and 
anti-CD28 coated beads. The positive control included responder 
cells alone with the addition of anti-CD3 and anti-CD28 coated 
beads at a bead + responder cell ratio of 1 + 4. The absolute cell 
concentration and cell density at the beginning of the coculture 
was 1 × 106/ml and 1 × 106/cm2 per well, respectively.
Cocultures were routinely performed in triplicates in 48-well 
plates and harvested after 60–72  h of incubation at 37 ±  1°C, 
5 ± 1% CO2, >70% r.h. After 60–72 h of incubation, conditions 
were harvested, stained with PI and CD8 as described under flow 
cytometry and acquired using a FACS Calibur (BD Biosciences). 
Data were analyzed using CellQuest™ Pro (BD Biosciences) 
software. Treg-mediated suppression was calculated based on the 
percentage of divided cells in the first cell generation with the 
positive control set to 100%. One cell generation was defined to 
contain at least ≥10% divided cells. Based on all cell generations, 
negative control cells should show less than 5% proliferated cells, 
and positive control cells should show more than 30% prolifer-
ated cells. Lot-release is based on the amount of Treg-mediated 
suppression in cocultures with a Treg to responder cell ratio of 
1 + 1, 1 + 5, and 1 + 10, respectively. For validation, more Treg to 
responder cell ratios were included. The results of the validation 
are summarized in Table 3.
Assessment of the Treg Drug Product Concerning 
Viability, Cell Number, Cell Concentration, Sterility, 
Bacterial Endotoxins, and Mycoplasma DNA
Cell number, cell concentration, and cell viability are determined 
by trypan blue staining and microscopic examination using a 
hemocytometer according to the method described in Ph. Eur. 
2.7.29. Sterility testing is routinely performed according to Ph. 
Eur. 2.6.1 by Bioservice Scientific Laboratories (BSL) GmbH, 
Planegg, Germany. Testing on bacterial endotoxins is routinely 
performed according to Ph. Eur. 2.6.14 by BSL. Testing on 
mycoplasma DNA is achieved by PCR by an in-house validated 
method by BSL.
t cell receptor (tcr) Vβ repertoire 
Analysis
The TCR Vβ repertoire of ex vivo generated CD25+ cells was 
determined by using the IO Test Beta Mark TCR Vβ Repertoire 
kit (Beckman Coulter, France) as previously published (28). Day 
0 derived CD25+ cells and day 21 CD25+ cells were stained and 
analyzed for TCR Vβ specificity according to the manufacturer’s 
instructions.
Epigenetic Analysis
Genomic cellular DNA was isolated using a high pure PCR 
template preparation kit (Roche). Next, sodium bisulfite conver-
sion of the purified DNA was performed by using the EpiTect® 
Fast DNA Bisulfite Kit (Qiagen) according to the manufacturer’s 
tABlE 3 | Validation results of analysis of regulatory T cell (Treg)-mediated 
suppression.
Validation part sample specificity result Passed
reproducibility
Coefficient of variation 2 + 1 ≤5% 0.3 X yes □ no
5 + 1 ≤5% 1.0 X yes □ no
10 + 1 ≤5% 2.2 X yes □ no
30 + 1 ≤5% 4.5 X yes □ no
50 + 1 ≤10% 4.9 X yes □ no
Intermediate precision
Deviation from mean 2 + 1 ≤±8% 5.0 X yes □ no
5 + 1 ≤±12% 7.2 X yes □ no
10 + 1 ≤±20% 12.5 X yes □ no
30 + 1 ≤±30% −5.6 X yes □ no
50 + 1 ≤±40% −39.8 X yes □ no
Coefficient of variation 2 + 1 ≤10% 2.8 X yes □ no
5 + 1 ≤10% 3.8 X yes □ no
10 + 1 ≤10% 5.4 X yes □ no
30 + 1 ≤15% 4.8 X yes □ no
50 + 1 ≤15% 8.0 X yes □ no
linearity
Coefficient of correlation 
in ascending range
100 + 1 to 5 + 1 ≥0.8 0.908 X yes □ no
Range All samples ≤10–≥90% 2.4–97.7% X yes □ no
Accuracy
Retrieval rate 1 + 1 100 ± 5% 99.7% X yes □ no
5 + 1 100 ± 5% 98.4% X yes □ no
10 + 1 100 ± 10% 108.8% X yes □ no
limit of detection
QL proliferation ≤1% 0.4% X yes □ no
QL suppression ≥95% 99.99% X yes □ no
Responder cells and Treg were mixed at the indicated ratios of 2 + 1, 5 + 1, 10 + 1, 
30 + 1, and 50 + 1. For reproducibility, triplicate analysis of responder cell to Treg ratios 
was statistically analyzed by coefficient of variation. The analysis of a different person 
on a different day was used to determine the intermediate precision. To determine 
linearity, 10 different responder cell to Treg ratios (1,000 + 1, 200 + 1, 100 + 1, 50 + 1, 
30 + 1, 10 + 1, 5 + 1, 2 + 1, 1 + 1, and 1 + 2) were analyzed by correlation factor 
and linear regression. These results were compared with the theoretical real fraction 
contents to determine accuracy. The limits of detection were determined by analyzing 
six non-stimulated responder cell to Treg mixtures (1 + 1) and calculated with the 
formula: 10s/a (s indicating SD and a indicating slope of regression).
QL, quantification limit.
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instructions. The following primers and probe enabled us to 
specifically detect methylated FoxP3 (29):
 5′-TGTCGATGAAGTTCGGCGTAT-3′ (forward)
 5′-CCCCCGACTTACCCAAATTT-3′ (reverse)
 6FAM-5′-CGGTCGTTATGACGTTAATGGCGGA-3′-
TAMRA (probe)
Primers and probes for the detection of unmethylated FoxP3 
were designed accordingly:
 5′-TGTTGATGAAGTTTGGTGTAT-3′ (forward)
 5′-CCCCCAACTTACCCAAATTT-3′ (reverse)
 6FAM-5′-TGGTTGTTATGATGTTAATGGTGGA-3′-
TAMRA (probe).
Quantitative PCR (qPCR) was performed by using the 
maxima probe qPCR master mix (ThermoFisher Scientific) and a 
C1000TM Thermal Cycler (Bio-Rad). Percentage of methylation 
in cells was calculated as Meth. [%] = 100/[1 + 2ΔCt(meth–unmeth)]% 
as recently described (30). ΔCt(meth − unmeth) represents the 
difference between the Ct value of methylated FoxP3 signal and 
Ct value of unmethylated FoxP3 value. Hypomethylation was 
calculated as hypometh. [%] = 100% − meth. [%]. Since the male 
FoxP3 Treg-specific demethylated region (TSDR) is described to 
be fully demethylated, and the female TSDR shows hemimethyla-
tion (31), the above described calculation would underestimate 
the relative number of hypomethylated Treg in cells derived from 
human donors. To circumvent an underestimation, the meth-
ylation index for female-derived probes was corrected using the 
following formula: meth. [%]female = meth. [%] −  (100 − meth. 
[%]). Similarly, hypomethylation in female derived probes was 
calculated as hypometh. [%] = 100% − meth. [%]female.
Assessment of Homing Markers
The homing potential of day 0 CD25+ cells and day 21 Treg drug 
product cells was assessed by staining with directly conjugated 
mAbs against CCR4 (clone L21H4), CCR8 (clone 191704), 
CD62L (clone DREG-56), CD103 (clone Ber-ATC8), CXCR3 
(clone G025H7), PSGL-1 (clone 688101), CCR9 (clone L053E8), 
CCR5 (clone HEK/1/85a), alpha4 Integrin (clone MZ18-24A9), 
beta7 Integrin (clone FIB27), and the purified mAb GPR15 (clone 
367902) with subsequent staining with specific mouse second-
ary IgG2b APC labeled antibody. Corresponding mouse isotype 
controls were included to assess unspecific binding. Cells were 
acquired using an LSR Fortessa (BD Biosciences), and data were 
analyzed using FlowJo software.
statistical Analysis
Statistical differences as measured by a two-sided paired 
Student t test were calculated using Excel v2010, based on 
the number of experiments as indicated in the figure legends. 
Differences were considered to be significant at a P value less 
than 0.05.
rEsUlts
treg Drug Product Expansion, Viability, 
and cell Number
To validate the established GMP-complaint production protocol 
and the predefined lot-release criteria, we performed four sub-
sequent Treg productions with a healthy donor-derived leuka-
pheresis product. Such a production is also called “consistency 
run” (hereafter called Con) and is executed by exactly following 
the predefined protocol and predefined lot-release criteria. 
A minimum of three consecutive Cons who pass all predefined 
lot-release criteria is required to obtain official GMP production 
approval from the German authorities. With use of the protocol, 
leukapheresis-derived CD25+ cells expanded greater than 2 
orders of magnitude with an average cell number of 113 × 106 
at day 7 (range 34 × 106–199 × 106), 501 × 106 at day 11 (range 
158 ×  106–849 ×  106), 635 ×  106 at day 14 (range 234 ×  106–
1,020 × 106), 986 × 106 at day 18 (range 159 × 106–2,074 × 106), 
and 1,076 ×  106 (range 528 ×  106–1,440 ×  106) at day 21 after 
FIGUrE 2 | Assessment of identity and cellular composition. (A) Representative FACS plots showing the gating strategy. (B) Representative FACS plots gated on 
PI− cells showing CD4, CD25, CD127, CD8, CD19, and CD56/CD16 expression after CD25+ cell enrichment at day 0 and after thawing the day 21 regulatory T cell 
(Treg) drug product. (c) Proportion of PI− cells expressing CD4, CD25, CD127, CD8, CD19, and CD56/CD16 after CD25+ cell enrichment at day 0 (n = 4, white 
bars) and after thawing the day 21 Treg drug product (n = 4, filled bars). ND, not determined.
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anti-CD3/anti-CD28 expander bead removal (Figures  2A,B). 
The exact starting Treg number and exact expansion rate per 
consistency run are shown in File S1 in Supplementary Material. 
In addition, cell viability met the predefined limit of ≥75% viable 
cells at day 7 (range 94.7–98.3%), day 11 (range 93.5–98.7%), day 
14 (range 95.8–97.6%), day 18 (range 94.3–98.8%), and day 21 
(range 92.9–98.3%) after anti-CD3/anti-CD28 expander bead 
removal in every consistency run (Table 4).
treg Drug Product sterility, Bacterial 
Endotoxins, and Mycoplasma DNA
One thawed vial of the day 21 Treg drug product from each 
consistency run was tested for its sterility and the presence of 
bacterial toxins and mycoplasma DNA. As confirmed by BSL, 
no bacterial growth was contaminating the Treg drug product 
after 21 days of expansion. Also, no bacterial endotoxins and no 
mycoplasma DNA could be detected (Table 4).
treg Drug Product Identity and cellular 
composition
The presence of CD4 (≥90.0%) and CD25 (≥80.0%) in combina-
tion with low to absent surface expression of CD127 (≤10.0%) is 
used to phenotypically discriminate Treg from effector T cells. 
This approach has been elected based on studies by Liu et  al. 
who reported that CD127 surface expression inversely correlates 
with FoxP3 and suppressive function of human CD4+ Treg3. 
A cutoff of more than 80.0 and 90.0% was chosen for CD25 
and CD4, respectively. A cutoff of less than 10.0% was chosen 
for CD127. Moreover, the Treg drug product cellular composi-
tion is guaranteed by the stringent cutoff criteria for potential 
CD8 (≤0.1%), CD19 (≤1.0%), and CD56/CD16 (≤1.0%) cells 
contaminating the Treg drug product. These cutoff criteria were 
based on the results of several clinical studies in our department 
with dendritic cells (32, 33). In these studies, a cellular con-
tamination, based on the sum of CD3+ T cells, CD19+ B cells, 
tABlE 4 | Good manufacturing practice-compliant production process evaluation.
Parameter limit con1 con2 con3 con4
Viable cells/ml ≥5.0 × 106 10.5 × 106 6.3 × 106 10.8 × 106 8.2 × 106
Cell viability (%) ≥75 96.7 92.8 96.8 96.9
Sterility No growth No growth No growth No growth No growth
Endotoxin (IU/ml) ≤30 ≤30 ≤30 ≤30 ≤30
Mycoplasma Negative Negative Negative Negative Negative
CD4 (%) ≥90.0 99.6 99.2 98.6 99.4
CD25 (%) ≥80.0 98.9 98.6 85.5 93.3
CD127 (%) ≥10.0 0.00 0.05 0.68 0.00
CD8 (%) ≤0.10 0.00 0.00 0.06 0.00
CD19 (%) ≤1.0 0.00 0.00 0.00 0.00
CD56/16 (%) ≤1.0 0.00 0.00 0.06 0.00
Labeling check reagent PE (%) ≤400 ≤400 ≤400 ≤400 ≤400
Labeling check reagent APC (%) ≤400 ≤400 ≤400 ≤400 ≤400
Suppression at ratio 1 + 1 (%) ≥80.0 99.5 81.4 98.2 99.9
Suppression at ratio 1 + 5 (%) ≥60.0 96.1 60.4 97.2 99.4
Suppression at ratio 1 + 10 (%) ≥50.0 85.4 52.5 61.6 83.2
Four successive regulatory T cell (Treg) productions were performed with healthy donor-derived leukapheresis products. Productions passed the indicated limits for release. Viable 
cells per milliliter indicate the total number of life retrieved Treg in the final Treg product. Viability indicates the percentage of life cells in the final Treg product. Sterility indicates 
bacterial growth contaminating the final Treg product. CD4, CD25, CD127, CD8, CD19, and CD56/CD16 indicate surface expression on the final Treg product. Labeling check 
reagent PE and APC indicate the remaining number of anti-CD3/anti-CD28 beads in the final Treg product. Suppression at ratio 1 + 1, 1 + 5, and 1 + 10 indicate the amount of 
suppression within the first generation of proliferating CD8+ responder cells by the final Treg product.
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and CD56+ NK-cells, of up to 10% of the total infused cells was 
tolerated well by patients with cutaneous or ocular melanoma. 
In the case of ex vivo expanded autologous Treg, contamination 
with CD8+ T cells potentially induces inflammation in patients 
with autoimmune disorders. Therefore, a cutoff of less than 
0.1% contaminating CD8+ cells was chosen for the release of 
the Treg drug product and a cutoff of less than 1.0% was chosen 
for contaminating CD19 and CD56/CD16 cells. Importantly, to 
reliably show less than 0.1% CD8+ cell contamination in the final 
Treg product, a total of 300,000 cells must be acquired by flow 
cytometry. As shown in Figure 2 and Table 4, the performed 
consistency runs passed the predefined lot-release criteria for 
product identity and cellular composition by the validated flow 
cytometry method. Specifically, an average of 99.2% CD4 (range 
98.6–99.6%), 94.1% CD25 (range 85.5–98.9%), 0.18% CD127 
(range 0.0–0.68%), 0.02% CD8 (range 0.0–0.06%), 0.0% CD19 
(range 0.0–0.0%), and 0.2% CD56/16 (range 0.0–0.06%) was 
determined in the thawed Treg drug products. In addition, as 
an internal scientific in-process control, intracellular FoxP3 
expression was determined on enriched day 0 CD25+ cells 
and day 21 expanded CD25+ cells (File S2 in Supplementary 
Material).
treg Drug Product Purity
The anti-CD3/anti-CD28 expander beads are removed from the 
cell product after 21 days of expansion using the CliniMACS® 
system. Although the CD25-, CD8-, and CD19-labeling beads 
generally are metabolized during the expansion process, poten-
tial remaining labeling beads will simultaneously be removed 
from the Treg drug product. As defined by our in-house validated 
bead removal method and shown in Figure 3 and Table 4, bead 
removal was efficient, since in a total of 100 ×  106 lysed Treg 
product cells less than 400 beads could be retrieved by flow 
cytometry.
treg Drug Product Function
Currently, the intracellular expression of FoxP3 is the most rec-
ognized marker to define Treg in human, yet intracellular FoxP3 
staining mostly shows high intra-sample variation. In addition, 
consensus on which antibody clone to include in staining proto-
cols is inconclusive (32–34). We, therefore, elected to omit FoxP3 
expression as a separate lot-release criterion. To compensate for 
the lack of a highly specific Treg marker as part of our lot-release 
criteria, we established a biologic assay confirming the suppres-
sive nature of the thawed Treg drug product. The objective was to 
reach ≥80.0% suppression within the first generation of divided 
cells at a responder cell to Treg ratio of 1 + 1, ≥60.0% suppres-
sion within the first generation of divided cells at a responder 
cell to Treg ratio of 1 + 5, and ≥50.0% suppression within the 
first generation of divided cells at a responder cell to Treg ratio 
of 1 +  10. In addition, suppression within the first generation 
of divided cells at a responder cell to Treg ratio of 1 + 1 had to 
exceed suppression within the first generation of divided cells at a 
responder cell to Treg ratio of 1 + 5. Likewise, suppression within 
the first generation of divided cells at a responder cell to Treg ratio 
of 1 + 5 had to exceed suppression within the first generation of 
divided cells at a responder cell to Treg ratio of 1 + 10. As shown 
in Figure 4 and Table 4, an average responder cell proliferation 
of 21.3% was observed within the first generation of divided cells 
when no Treg were added to the coculture. In the presence of 
Treg at a ratio of 1 +  1, responder cells showed an average of 
1.09% of proliferation within the first generation of divided cells, 
whereas 2.37 and 6.62% of proliferation was observed at a ratio 
of 1 + 5 and 1 + 10, respectively (Figure 4C). The Treg-mediated 
suppression within the first generation of divided cells was 
calculated with the positive control set to 100%, resulting in an 
average suppression of 94.7% at a responder cell to Treg ratio of 
1 + 1 (range 81.4–99.9%), 88.3% suppression at a responder cell 
to Treg ratio of 1 + 5 (range 60.4–99.3%) and 70.7% suppression 
FIGUrE 3 | Assessment of regulatory T cell (Treg) drug product purity. (A) Representative FACS plots gated on PE+/APC+ anti-CD3/anti-CD28 expander beads in a 
control sample containing no anti-CD3/anti-CD28 expander beads (=background sample), a control sample containing 750 anti-CD3/anti-CD28 expander beads 
(=negative control sample), a control sample containing 1,000 anti-CD3/anti-CD28 expander beads (=standard sample), and a control sampler containing 3,000 
anti-CD3/anti-CD28 expander beads. (B) FACS plots gated on PE+/APC+ anti-CD3/anti-CD28 expander beads in a thawed Treg drug product from consistency  
run 1 (=Con1), consistency run 2 (=Con2), consistency run 3 (=Con3), and consistency run 4 (=Con4).
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at a responder cell to Treg ratio of 1 +  10 (range 52.5–85.5%) 
(Figure  4D). In addition, average suppression within the first 
generation of divided cells at a responder cell to Treg ratio of 1 + 1 
exceeded suppression within the first generation of divided cells 
at a responder to Treg ratio of 1 + 5. Likewise, average suppres-
sion within the first generation of divided cells at a responder 
cell to Treg ratio of 1 + 5 exceeded suppression within the first 
generation of divided cells at a responder to Treg ratio of 1 + 10. 
Moreover, based on all proliferated CD8+ cells, including all cell 
generations, a gradual increase in mean fluorescence intensity 
(MFI) was observed with increasing Treg to responder cell 
ratios with a mean MFI of 522.8 (range 440–705) at a Treg to 
responder cell ratio of 1 + 10 and a mean MFI of 667.5 (range 
539–893) at a Treg to responder cell ratio of 1 + 1 (File S3A–C 
in Supplementary Material). Likewise, a reduction in the total 
number of cell generations was observed with increasing Treg to 
responder cell ratios (File S3D in Supplementary Material).
treg Drug Product stability
Stability data were acquired with Treg drug products that 
were continuously stored in the gas phase of liquid nitrogen 
≤−150°C for at least 12  months. Stored Treg drug products 
were thawed and analyzed according to the criteria defined 
for lot-release. Microbial testing, phenotyping, cellular com-
position, viability, recovery, and function met the limits of 
the drug product in every case for up to 12 months (Table 5). 
Therefore, guaranteed stability for the Treg drug product was 
set at 12 months.
Moreover, Treg drug products stored for at least 12 months 
from each consistency run were thawed, diluted with 0.9% sodium 
chloride solution and incubated for 90 min at 30 ± 1°C to mimic 
the preparation of the Treg drug product for adoptive transfer 
in clinical settings. After 90 min of incubation at 30 ± 1°C in a 
0.9% sodium chloride solution, phenotype, cellular composition, 
viability, recovery, and function met the preset limits of the drug 
product in all tested products (Table 6).
treg Drug Products Are Polyclonal, 
Hypomethylated, and Express Various 
Markers Associated with tissue Homing
To rule out the outgrowth of monoclonal Treg clones during the 
GMP-compliant production process, Treg drug products were 
thawed and stained with a panel of 24 distinct TCR Vβ mono-
clonal antibodies, which cover approximately 70% of the human 
TCR Vβ repertoire. As shown in Figure 5A, both enriched day 
0 CD25+ cells and day 21 Treg expressed all 24 TCRs, indicating 
that the produced Treg remain polyclonal. In addition, GMP-
compliant Treg production does not affect hypomethylation of the 
Treg at intron 1 of the FoxP3 locus, since no significant difference 
in hypomethylation was found between enriched day 0 CD25+ 
cells and day 21 Treg drug products (P = 0.5111, Figure 5B).
Moreover, as shown in Figure  6, the Treg drug product 
expressed various receptors associated with lymphocyte traf-
ficking into tissues and to sites of inflammation. Specifically, 
expanded Treg expressed moderate to high levels of PSGL-1, 
α4β7 integrin, CD103, CCR4, and CD62L and expression lev-
els significantly increased during the expansion process with 
P = 0.0022 for PSGL-1, P = 0.0073 for α4β7 integrin, P = 0.0138 
for CD103, P =  0.0248 for CCR4, and P =  0.0036 for CD62L. 
tABlE 5 | Results of regulatory T cell (Treg) drug product stability testing after at least 12 months of storage.
Parameter con1 con2 con3 con4 Acceptance 
criteria
criteria 
passed
release >12 months release >12 months release >12 months release >12 months
CD4 (%) 99.6 99.7 99.2 99.2 98.6 98.7 99.4 99.3 ≥90.0 Yes
CD25 (%) 98.9 95.7 98.6 98.3 85.5 81.9 93.3 93.8 ≥80.0 Yes
CD127 (%) 0.0 1.4 0.1 2.5 0.7 1.6 0.0 1.2 ≤10.0 Yes
CD8 (%) 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.1 ≤0.5 Yes
CD19 (%) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 ≤1.0 Yes
CD56/16 (%) 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 ≤1.0 Yes
Suppression at ratio 1 + 1 (%) 99.5 95.2 81.4 99.4 98.2 96.1 99.9 98.4 ≥80.0 Yes
Suppression at ratio 5 + 1 (%) 96.1 80.8 60.4 85.9 97.2 66.9 99.4 79.2 ≥60.0 Yes
Suppression at ratio 10 + 1 (%) 85.4 66.5 52.5 65.9 61.6 61.8 83.2 70.8 ≥50.0 Yes
viable cells/ml (×106) 10.5 9.3 6.3 9.1 10.8 9.8 8.2 7.9 ≥5.0 Yes
Cell viability (%) 96.7 78.7 92.8 79.7 96.8 84.1 96.9 74.1 ≥50.0 Yes
Sterility ng ng ng ng ng ng ng ng ng Yes
Endotoxin (IE/ml) <30 <30 <30 <30 <30 <30 <30 <30 <30 Yes
Mycoplasma neg neg neg neg neg neg neg neg neg Yes
Treg were thawed after a minimum of 24 h after production or after at least 12 months of storage at ≤−150°C and analyzed for lot-release. CD4, CD25, CD127, CD8, CD19, and 
CD56/CD16 indicate surface expression on the final Treg product. Suppression at ratio 1 + 1, 1 + 5, and 1 + 10 indicate the amount of suppression within the first generation of 
proliferating CD8+ responder cells by the final Treg product. Viable cells per milliliter indicate the total number of life retrieved Treg in the final Treg product. Viability indicates the 
percentage of life cells in the final Treg product. Sterility indicates bacterial growth contaminating the final Treg product.
ng, no growth; neg, negative.
FIGUrE 4 | Assessment of regulatory T cell (Treg) drug product function. (A) Representative FACS plots showing the gating strategy defining CD25− responder cell 
proliferation. (B) Representative histograms gated on CD8+/CFSE+ responder cells showing percentage of responder cell proliferation within the most divided cell 
generation in the presence of the thawed day 21 Treg drug product cells at a Treg to responder cell ratio of 1 + 1, 1 + 5, and 1 + 10, respectively. (c) Proportion of 
the first generation of responder cells (n = 4) showing proliferation in the presence of no anti-CD3/anti-CD28 beads (=negative control), in the presence of anti-CD3/
anti-CD28 beads (=positive control) and at a Treg to responder cell ratio of 1 + 1 (mean 1.09%), 1 + 5 (mean 2.37%), and 1 + 10 (mean 6.62%), respectively. (D) 
Amount of suppression in the first generation of divided cells at a Treg to responder cell ratio of 1 + 1 (mean 94.7%), 1 + 5 (mean 88.3%), and 1 + 10 (mean 70.7%).
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tABlE 6 | Results of regulatory T cell (Treg) drug product stability testing in the clinical application solution.
Parameter con1 con2 con3 con4 Acceptance 
criteria
criteria passed
0.5 × 106/ml 20 × 106/ml 0.5 × 106/ml 20 × 106/ml 0.5 × 106/ml 20 × 106/ml 0.5 × 106/ml 20 × 106/ml
CD4 (%) 93.2 98.9 97.3 98.2 98.7 98.4 99.5 99.4 ≥90.0 Yes
CD25 (%) 89.1 87.5 86.1 96.6 81.1 86.0 95.9 94.6 ≥80.0 Yes
CD127 (%) 0.2 0.1 0.9 0.0 6.8 4.8 3.3 1.9 ≤10.0 Yes
CD8 (%) 0.0 0.1 0.0 0.0 0.1 0.1 0.0 0.1 ≤0.5 Yes
CD19 (%) 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 ≤1.0 Yes
CD56/16 (%) 0.0 0.4 0.0 0.0 0.0 0.0 0.0 0.0 ≤1.0 Yes
Suppression at ratio 1 + 1 (%) 97.7 96.5 98.8 97.6 97.0 96.5 93.5 96.6 ≥80.0 Yes
Suppression at ratio 5 + 1 (%) 90.3 91.7 94.7 96.2 91.7 76.1 82.5 92.6 ≥60.0 Yes
Suppression at ratio 10 + 1 (%) 81.6 87.1 70.3 70.3 78.5 63.6 56.9 55.2 ≥50.0 Yes
Viable cells/ml (×106) 7.3 6.7 6.1 5.7 6.0 5.5 7.1 5.7 ≥5.0 Yes
Viability (%) 76.1 70.5 78.0 70.6 77.2 79.1 74.9 76.3 ≥50.0 Yes
Treg were thawed at least 12 months after storage at ≤−150°C and analyzed for stability in a 0.9% sodium chloride solution at indicated Treg concentrations. CD4, CD25, CD127, 
CD8, CD19, and CD56/CD16 indicate surface expression on the final Treg product. Suppression at ratio 1 + 1, 1 + 5, and 1 + 10 indicate the amount of suppression within the 
first generation of proliferating CD8+ responder cells by the final Treg product. Viable cells per milliliter indicate the total number of life retrieved Treg in the final Treg product. Viability 
indicates the percentage of life cells in the final Treg product.
FIGUrE 5 | The regulatory T cell (Treg) drug product is polycloncal and hypomethylated at intron 1 of the FoxP3 locus. (A) Proportion of Treg expressing indicated 
T cell receptor Vβ subtype after CD25+ cell enrichment at day 0 (n = 4, white bars) and after 21 days of ex vivo expansion (n = 4, filled bars). (B) Percentage 
hypomethylation at intron 1 of the FoxP3 locus after CD25+ cell enrichment at day 0 (n = 4, white bar) and after 21 days of ex vivo expansion (n = 4, filled bar). NS, 
not significant.
13
Wiesinger et al. GMP-Compliant Treg Production
Frontiers in Immunology | www.frontiersin.org October 2017 | Volume 8 | Article 1371
Also, high levels of CCR5 and CXCR3 were expressed on both 
day 0 CD25+ enriched cells and day 21 Treg, whereas only little 
to moderate expression levels of CCR8, CCR9, and GPR15 were 
detected.
risk Management and limits of Detection
A major risk in the presented protocol is the detection of human 
immunodeficiency virus (HIV), hepatitis B virus (HBV), or 
hepatitis C virus (HCV) antigens or microbiological impurities 
FIGUrE 6 | Markers associated with homing are significantly expressed on the regulatory T cell (Treg) drug product. Proportion of CD25+ cells at day 0 (white bars) 
and day 21 Treg drug product cells (filled bars) expressing CCR4 (n = 4), PSG-1 (n = 4), CCR9 (n = 4), CCR5 (n = 4), α4β7 (n = 4), CD103 (n = 4), CD62L (n = 4), 
CXCR3 (n = 4), CCR8 (n = 4), and GPR15 (n = 4). NS, not significant, *P < 0.05.
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in the patient material or final Treg product. When the leuca-
pherisate is tested positive for HIV, HBV, or HCV, the production 
process is stopped immediately, and cell cultures will be destroyed 
accordingly. When the final drug product is tested positive for 
microbiological impurities, the product will be placed into quar-
antine, and is not released for clinical treatment. Confirmation 
tests will be performed to define if the product remains positive, 
and will be destroyed or was tested false positive.
Other Treg production risks include a low number of Treg after 
21 days of expansion. In this case, the amount of cells regularly 
used for lot-release (120 × 106) could be reduced accordingly. Any 
out of specification result for Treg phenotype or Treg function 
results in the non-release of the Treg product. However, if the 
number of CD8+ cells, CD19+ cells, and/or anti-CD3/anti-CD28 
expander beads exceeds the specification, the CD8+/CD19+ cell 
depletion and/or anti-CD3/anti-CD28 expander bead removal 
step could be repeated. Applicable limits of detection and quanti-
fication are provided in Tables 1–3, respectively.
DIscUssIoN
Here, we show, for the first time, an official authority GMP-
approved protocol to produce large numbers of ex vivo rapam-
ycin-expanded CD25+ cells intended to treat inflammatory and 
autoimmune disorders. In addition, we provide the complete 
testing and validation of the lot-release of the final Treg drug 
product after freezing and thawing. Moreover, we extended 
traditional lot-release criteria and added a functional biological 
assay assuring the suppressive nature of the produced Treg cells 
at different Treg-to-effector T cell ratios. Thus far, published clini-
cal studies testing adoptively transferred Treg included classical 
suppression assays as part of the immune-monitoring assays (18) 
after treatment of the patients to correlate clinical outcome with 
in  vitro Treg function, but the delivered Treg product did not 
undergo potency testing before administration to the patient. By 
contrast, this Treg product is not released for clinical treatment 
unless in vitro suppression is proven at various cell ratios for each 
batch of Treg.
All the consistency runs met the specifications of the process 
and the product, including sterility, Treg phenotype, non-Treg cel-
lular contamination, anti-CD3/anti-CD28 expander bead purity, 
and Treg function after freezing and thawing. This contrasts the 
general consideration that cryopreservation of Treg products is 
challenging (35) and that stimulation and expansion steps are 
necessary to restore Treg function after thawing (36).
Stability data were acquired with Treg, which were continu-
ously stored in the gas phase of liquid nitrogen at ≤150°C for at 
least 12 months. Stored Treg were shown to retain Treg phenotype 
and function. Therefore, as advocated by Singer et al. (12), our 
Treg drug product could facilitate an “on demand” treatment 
for an acute inflammatory disease or acute allograft rejection 
without the time delay required for Treg enrichment and expan-
sion. Moreover, since stability is warranted for at least 12 months, 
multiple Treg doses could be administered to the patient at dif-
ferent time points.
Besides Treg drug product stability after freezing and thawing, 
the Treg also remained stable after dilution in a 0.9% physiologi-
cal saline infusion solution for up to 90 min. This is an important 
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assurance, since the Treg drug product will be transferred intra-
venously through continuous infusion using 50 ml syringes in a 
perfusion pump.
Importantly, this Treg expansion protocol has several differ-
ences compared with the Treg expansion protocol intended to 
treat patients after liver transplantation (27). First, the presented 
production protocol reaches clinically relevant Treg numbers 
after 21 days of expansion without the need to re-stimulate the 
expanding Treg. Second, less than 0.1% of contaminating CD8+ 
effector cells were present in the released Treg product. This is a 
fraction of the allowed 10% CD8+ effector cells in the Treg product 
intended to prevent liver rejection. Third, expanded Treg remain 
hypomethylated at intron 1 of the FoxP3 locus, confirming their 
epigenetic stability. Finally, the produced Treg show suppressive 
function against autologous CD8+ effector cells at various Treg-
to-effector cell ratios; whereas the Treg produced to prevent liver 
rejection showed suppression of allogeneic effector cells at one 
Treg-to-effector cell ratio.
In the past years, several clinical studies employing expanded 
Treg have been conducted. The majority of studies included 
patients at risk for GvHD (14–16) or organ rejection (37, 38) after 
transplantation. These studies either infused ex vivo expanded 
Treg (14–16) or freshly isolated non-expanded Treg cells (39, 40). 
Treg infusions were well tolerated and no dose-limiting toxicities 
were reported (14, 15). In addition, the onset of both acute and 
chronic GvHD was favorably affected compared with historical 
controls and no adverse effects on non-relapse mortality or 
relapse were detected within a minimum follow-up of 2  years 
(14, 15). In addition, the possibility of adoptive Treg to ameliorate 
insulin dependency in both children and adults has been reported 
(17, 18). In these studies, Treg transfer was safe and not associ-
ated with serious adverse events in the treated children (17). By 
contrast, four serious adverse events were reported in the treated 
adults (18). Specifically, one patient experienced three episodes of 
serious hypoglycemia 14, 248, and 463 days after Treg treatment, 
and one patient experienced an episode of diabetic ketoacidosis 
67 days after Treg treatment. Interestingly, by labeling with [6,6-
2H2] glucose, Treg were demonstrated to persist in the peripheral 
circulation for up to one year after transfer (18). Finally, the 
safety and efficacy of ex vivo expanded ovalbumin-specific IL-10-
producing Treg has been assessed in patients with Crohn’s disease 
(CD). The safety profile in this pilot study showed good toler-
ability and adverse events reflected the underlying CD. Moreover, 
a clinical significant improvement of disease symptoms was noted 
5 weeks after Treg infusion in 40% of patients (41).
In conclusion, Treg produced by the presented method have 
broad clinical potential. Based on the fact that the presented 
Treg drug product is polyclonal and expressing various recep-
tors associated with (i) lymphocyte trafficking into the skin (42, 
43) (e.g., CCR4 and CD103), (ii) homing into lymphoid organs 
(44, 45) (e.g., PSGL-1 and CD62L), (iii) homing to the intestinal 
mucosa (46, 47) (e.g., CCR9 and α4β7 integrin), and (iv) sites of 
inflammation (45, 48, 49) (e.g., PSGL-1, CD103, and CXCR3), 
the Treg could be effective in clinical studies aiming to treat 
various autoimmune-based and inflammatory disorders such as 
skin diseases, rheumatic diseases, intestinal inflammation, and 
graft-versus-host disease.
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